Moderna CEO St茅phane Bancel. Credit: World Economic Forum / Greg Beadle

is aiming to market a Covid-19 and influenza booster vaccine combo within the next two years, CEO St茅phane Bancel has said.

The single shot offering protection against Covid-19, flu, and the common respiratory virus RSV could be ready ahead of 2023鈥檚 winter infectious season, he announced.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

鈥淥ur goal is to be able to have a single annual booster so that we don鈥檛 have compliance issues where people don鈥檛 want to get two-to-three shots a winter,鈥� Bancel said, speaking at a on Monday (17 January).

The US-based company first shared plans to develop a single jab combining its Covid-19 booster with a flu shot back in September, during a presentation to investors.

At the time, Bancel said Moderna could be the first company to bring a 鈥渉igh efficacy, pan-respiratory annual booster鈥� to market.

The CEO also told Monday鈥檚 panel that a Moderna Covid-19 vaccine candidate targeting the highly transmissible Omicron variant will enter clinical development in the coming weeks. He added that data on the Omicron-specific jab could be shared with regulators as soon as March.

While many countries are now rolling out third shots of coronavirus vaccines to boost populations鈥� immunity against Covid-19, Bancel commented earlier this month that a fourth jab could be needed this year as the efficacy of initial vaccinations and booster doses declines.

In December, Israel began administering second booster doses to its most vulnerable or high-risk populations. This week, a preliminary study conducted in the country suggested a fourth Covid-19 vaccine shot helps to boost antibodies but does not provide enough protection to prevent Omicron infections.

Covid-19 vaccines: our most read articles